J. Pena

Meeting abstracts from the 9th International Conference on cGMP: Generators, Effectors and Therapeutic Implications

Alexander G. B. Grønning, Harald H. H. W. Schmidt, M. Cerinic, 2019, Journal of Translational Medicine.

PULSAR: A phase 2, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of sotatercept (ACE-011) when added to standard of care (SOC) for treatment of pulmonary arterial hypertension (PAH)

M. Humbert, R. Zeldin, D. Badesch, 2019, Pulmonary hypertension.

OP0184 PROFIBROTIC LNCRNA H19X: UNRAVELLING THE EFFECTS ON CHROMATIN REMODELING IN SYSTEMIC SCLEROSIS FIBROBLASTS

C. Denton, D. Khanna, M. Matucci-Cerinic, 2019, Oral Presentations.

FRI0303 THE EFFECTS OF RIOCIGUAT ON RAYNAUD’S PHENOMENON AND DIGITAL ULCERS IN PATIENTS WITH DIFFUSE SYSTEMIC SCLEROSIS: RESULTS FROM THE PHASE IIB RISE-SSC STUDY

C. Denton, D. Khanna, M. Matucci-Cerinic, 2019, Scleroderma, myositis and related syndromes.

SAT0513 Progressive skin fibrosis is associated with a decline in lung function and poorer survival in patients with diffuse cutaneous systemic sclerosis: a european scleroderma trials and research (EUSTAR) analysis

D. Khanna, M. Matucci-Cerinic, Y. Allanore, 2018, Saturday, 16 JUNE 2018.

AB0627 Rise-ssc: a double-blind, randomised study evaluating the efficacy and safety of riociguat for the treatment of patients with diffuse cutaneous systemic sclerosis

C. Denton, D. Khanna, M. Matucci-Cerinic, 2017 .